KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Assets Average (2019 - 2025)

Adaptive Biotechnologies' Assets Average history spans 7 years, with the latest figure at $501.7 million for Q4 2025.

  • For Q4 2025, Assets Average fell 8.61% year-over-year to $501.7 million; the TTM value through Dec 2025 reached $501.7 million, down 8.61%, while the annual FY2025 figure was $526.1 million, 12.36% down from the prior year.
  • Assets Average for Q4 2025 was $501.7 million at Adaptive Biotechnologies, up from $493.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.1 billion in Q1 2021 and bottomed at $493.6 million in Q3 2025.
  • The 5-year median for Assets Average is $759.6 million (2023), against an average of $748.9 million.
  • The largest annual shift saw Assets Average rose 22.46% in 2021 before it fell 22.86% in 2024.
  • A 5-year view of Assets Average shows it stood at $958.0 million in 2021, then decreased by 9.14% to $870.4 million in 2022, then dropped by 20.8% to $689.4 million in 2023, then fell by 20.38% to $548.9 million in 2024, then fell by 8.61% to $501.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Assets Average are $501.7 million (Q4 2025), $493.6 million (Q3 2025), and $503.7 million (Q2 2025).